| ★ | Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | |
| 8 | Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 72 |
| 6 | IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 73 |
| 15 | From basics to updates for cutaneous lupus erythematosus (CLE) | | 1.1K | — | 70 |
| 7 | Steroids in Relapsing Polychondritis | | 474 | — | 73 |
| 20 | CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 69 |
| 9 | What is the added value of triple therapy in lupus nephritis? | | 438 | — | 72 |
| 2 | Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 74 |
| 18 | Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 69 |
| 4 | Autoantibodies and clinical phenotypes in Idiopathic Inflammatory Myopathies (IIMs) | | 286 | — | 74 |
| 16 | Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | 70 |
| 11 | Microvascular Involvement in Antiphospholipid Syndrome (APS) | | 264 | — | 71 |
| 12 | Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 71 |
| 19 | Exercise in adult idiopathic inflammatory myopathies (IIMs) | | 188 | — | 69 |
| 3 | Everything you always wanted to know about Ehlers-Danlos Syndromes (EDS) – Part two | | 151 | — | 74 |
| 1 | Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 76 |
| 17 | Obstetric manifestations in past and present antiphospholipid syndrome (APS) classification criteria | | 94 | — | 70 |
| 14 | Chat-GPT and more – how AI will revolutionize medicine and the management of rare diseases | | 71 | — | 70 |
| 5 | Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 74 |
| 13 | “Doctor, can you ask me…?” for connective tissue diseases patients | | 46 | — | 70 |
| 10 | Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 71 |